Yahoo
NasdaqCM - Delayed Quote USD

Rallybio Corporation (RLYB)

15.54 +0.01 (+0.06%)
At close: October 30 at 4:00:00 PM EDT
Chart Range Bar
Loading chart for RLYB
  • Previous Close 15.53
  • Open 15.42
  • Bid 12.06 x 200
  • Ask 16.82 x 100
  • Day's Range 15.30 - 16.25
  • 52 Week Range 3.67 - 17.57
  • Volume 61,715
  • Avg. Volume 16,282
  • Market Cap (intraday) 83.666M
  • Beta (5Y Monthly) -0.71
  • PE Ratio (TTM) 3.37
  • EPS (TTM) 4.61
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.

www.rallybio.com

6

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

RLYB
183.16%
S&P 500 (^GSPC)
10.73%

1-Year Return

RLYB
178.69%
S&P 500 (^GSPC)
11.11%

3-Year Return

RLYB
55.75%
S&P 500 (^GSPC)
81.91%

5-Year Return

RLYB
89.12%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings --
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-5M
0
5M
10M
15M
-2000.0%
0.0%
2000.0%
4000.0%
6000.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    6,177.42%

  • Return on Assets (ttm)

    -16.79%

  • Return on Equity (ttm)

    34.52%

  • Revenue (ttm)

    434k

  • Net Income Avi to Common (ttm)

    26.81M

  • Diluted EPS (ttm)

    4.61

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    90.69M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -9.39M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: